1. Montanya E, Rosenstock J, Canani LH, et al. Oral semaglutide vs empagliflozin added-on to metformin monotherapy in uncontrolled type 2 diabetes: PIONEER 2. Abstract number 54-OR, American Diabetes Association 79(th) Scientific Session, San Francisco, US; 7-11 June 2019 2. Pratley RE, Amod A, Hoff ST, et al. Oral Semaglutide vs Liraglutide and Placebo in T2D: PIONEER 4. Abstract number 55-OR, American Diabetes Association 79(th) Scientific Session, San Francisco, US; 7-11 June 2019
Further information
Media: Katrine Sperling +45 4442 6718 krsp@novonordisk.com Michael Bachner (US) +1 609 664 7308 mzyb@novonordisk.com Investors: Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com Ann Sndermlle Rendbk +45 3075 2253 arnd@novonordisk.com Kristoffer Due Berg (US) +1 609 235 2989 krdb@novonordisk.com
Web site: http://novonordisk.com/
